Search results
Showing 16 to 30 of 43 results for botulinum toxin type a
Occipital nerve stimulation for intractable chronic migraine (IPG452)
Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.
View recommendations for IPG452Show all sections
Sections for IPG452
Transcranial magnetic stimulation for treating and preventing migraine (IPG477)
Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve to treat cluster headache and migraine in adults. This involves using a small handheld device to stimulate a nerve in the neck.
Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.
View recommendations for IPG740Show all sections
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
Question Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum...
Functional electrical stimulation for drop foot of central neurological origin (IPG278)
Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.
View recommendations for IPG278Show all sections
Sections for IPG278
This guideline covers advice on the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
In development [GID-TAG499] Expected publication date: TBC
This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.
CG148/5 Question What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and...
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
reported. Source guidance details Comes from guidance Botulinum toxin type A injections into the urethral sphincter for idiopathic...
This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.
View quality statements for QS77Show all sections
Sections for QS77
- Quality statements
- Quality statement 1: Initial assessment
- Quality statement 2: Bladder diaries and lifestyle changes
- Quality statement 3: Containment products
- Quality statement 4: Supervised pelvic floor muscle training
- Quality statement 5: Bladder training
- Quality statement 6: Indwelling catheters
- Quality statement 7: Multidisciplinary team review before surgery or invasive treatment